New Research Points to Potential for More Targeted Treatments of Deadly Neuroblastoma Tumors in Children
Genetic variations appear to pre-dispose children to developing certain severe forms of neuroblastoma, according to new research by the University of Chicago Medicine. The findings lay the groundwork for developing more targeted treatments for particularly deadly variations of the cancer. Neuroblastoma affects about 1,000 children in the U.S. per year. Patients are placed into different risk categories for their disease. Each risk category determines the intensity of the treatment regimen and likelihood of a patient’s survival. Children in lower-risk categories experience a roughly 95 percent survival rate with minimal treatment. But, if a child is classified as high-risk, the survival rate falls to approximately 50 percent even with an aggressive treatment plan that includes high-dose chemotherapy, surgery, stem cell transplant, radiation and immunotherapy. One common indicator of high-risk cancer is if a child has extra copies (amplification) of a gene called MYCN (pronounced mick-N).
Click here to read more.
Winter Clinics for Cranial and Spinal Surgery
Feb. 25, 2018 - Mar. 1, 2018; Snowmass Village, Colo.
69th Southern Neurosurgical Society Annual Meeting
Feb. 28, 2018 - Mar. 3, 2018; San Juan, PR
Second International Brain Mapping Course
April 26-27, 2018; New Orleans
2018 AANS Annual Scientific Meeting
April 28-May 2, 2018; New Orleans
2018 American Society for Stereotactic and Functional Neurosurgery Biennial Meeting
Jun. 2, 2018 - Jun. 5, 2018; Denver